<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="case-report" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2026.1759311</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Case Report: A case of toxic epidermal necrolysis induced by serplulimab: integrated Chinese and Western nursing care</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname> <given-names>Dan</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3302526"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
</contrib-group>
<aff id="aff1"><institution>The Third Hospital of Mianyang, Sichuan Mental Health Center</institution>, <city>Mianying</city>, <state>Sichuan</state>, <country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Dan Wang, <email xlink:href="mailto:wangdan1@stu.cdutcm.edu.cn">wangdan1@stu.cdutcm.edu.cn</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-16">
<day>16</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>13</volume>
<elocation-id>1759311</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>12</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Wang.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Wang</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-16">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>This study summarizes the integrated Chinese and Western medical nursing experience for a lung cancer patient admitted to our hospital in 2025 who developed toxic epidermal necrolysis (TEN) following treatment with serplulimab. Medical staff provided personalized care addressing the patient&#x2019;s skin and mucosal lesions, pain, and psychological wellbeing, aiming to establish evidence for the future treatment and management of such symptoms. Following multidisciplinary consultation and 39&#x202F;days of meticulous treatment and nursing care, the patient&#x2019;s widespread skin erosion largely healed, with no new rashes observed, ultimately leading to discharge in an improved condition.</p>
</abstract>
<kwd-group>
<kwd>cancer</kwd>
<kwd>combined Chinese and Western medicine care</kwd>
<kwd>nursing experience</kwd>
<kwd>skin lesion care</kwd>
<kwd>toxic epidermal necrolysis</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="3"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="43"/>
<page-count count="8"/>
<word-count count="6469"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Dermatology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>With the acceleration of population aging and changes in lifestyle, patterns of cancer incidence and mortality have shifted. As a result, the overall cancer disease burden continues to increase, and the challenges of prevention and control are becoming increasingly severe (<xref ref-type="bibr" rid="ref1">1</xref>). Globally, lung cancer is undoubtedly the leading malignant tumor in terms of both incidence and mortality (<xref ref-type="bibr" rid="ref1">1</xref>). Pathologically, small-cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. It is the most aggressive subtype, characterized by rapid progression, high metastatic potential, and poor prognosis (<xref ref-type="bibr" rid="ref2">2</xref>). Clinically, SCLC is typically categorized into two main stages: limited stage and extensive stage. The majority of lung cancer patients are already in the extensive stage at diagnosis, resulting in a generally poor overall prognosis (<xref ref-type="bibr" rid="ref2">2</xref>).</p>
<p>Serplulimab is an innovative antitumor drug and China&#x2019;s domestically developed PD-1 monoclonal antibody. It tightly binds to PD-1, thereby blocking the interaction between PD-1 and its ligand PD-L1. This action disrupts the immune escape mechanism of tumor cells, thereby enhancing the killing effect of tumor antigen-specific T cells on tumor cells. Serplulimab has exhibited remarkable efficacy and safety in multiple clinical trials (<xref ref-type="bibr" rid="ref3">3</xref>). As an innovative PD-1 inhibitor, serplulimab was evaluated in the landmark ASTRUM-005 study exploring efficacy and safety in extensive-stage small-cell lung cancer (ES-SCLC). This trial provided high-level evidence-based medical data that reshaped the landscape of first-line ES-SCLC treatment (<xref ref-type="bibr" rid="ref4">4</xref>). In January 2023, the National Medical Products Administration (NMPA) approved the indication of serplulimab in combination with carboplatin and etoposide for the first-line treatment of ES-SCLC (<xref ref-type="bibr" rid="ref5">5</xref>).</p>
<p>Due to the similarity of antigens between tumor cells and normal cells, the immune system may attack normal tissues while eliminating tumors, leading to various toxic reactions, including skin toxicity, hematologic toxicity, gastrointestinal toxicity, neurological toxicity, respiratory toxicity, and nephrotoxicity (<xref ref-type="bibr" rid="ref6">6</xref>). These toxic reactions often manifest as skin-related disorders and colitis, with less common occurrences including hepatitis, pneumonia, myocarditis, endocrine system disorders, neurological disorders, and rheumatologic/immune system disorders. Previous studies and reports have indicated that approximately 9.5% of patients treated with serplulimab experience grade 3 or higher immune-related adverse events (irAEs), with skin-related irAEs being the most common type of irAEs (<xref ref-type="bibr" rid="ref7">7</xref>). A meta-analysis evaluating the safety of inhibitors such as serplulimab has also indicated that the overall incidence of adverse events ranged between 54 and 76% (<xref ref-type="bibr" rid="ref8">8</xref>). Skin irAEs were the most frequently observed, occurring in more than 30% of patients and often being the first adverse reaction detected.</p>
<p>Toxic epidermal necrolysis (TEN) is a rare, acute, severe dermatological condition characterized by epidermal necrosis exceeding 30% of the total body surface area (TBSA), with an annual incidence reported at only 1&#x2013;7 cases per million (<xref ref-type="bibr" rid="ref9">9</xref>). Its clinical manifestations primarily include blistering, epidermal detachment, and mucositis affecting multiple sites. Drug-induced adverse reactions are common triggers, including anticonvulsants, antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), anti-infective agents, and the increasingly prevalent targeted therapies (<xref ref-type="bibr" rid="ref10">10</xref>). TEN represents a critical illness characterized by an abrupt onset and rapid progression. The majority of cases involve extensive epidermal necrosis and desquamation, frequently complicated by systemic organ failure, electrolyte imbalances, and sepsis, resulting in high mortality rates (<xref ref-type="bibr" rid="ref11 ref12 ref13">11&#x2013;13</xref>). Mortality is positively correlated with the extent of skin involvement, making management of cutaneous lesions a major challenge in care.</p>
<p>Traditional Chinese medicine does not classify severe drug eruptions as a distinct disease entity but rather categorizes them under &#x201C;drug toxicity.&#x201D; This condition primarily arises from a patient&#x2019;s constitutional weakness and subsequent invasion by drug toxins. TCM treatment completely leverages the holistic concept, tailoring therapies to each patient&#x2019;s unique pattern differentiation, thereby enhancing efficacy (<xref ref-type="bibr" rid="ref14">14</xref>). Existing research has indicated that TCM plays a significant role in the clinical prevention and treatment of skin adverse reactions associated with anticancer drugs (<xref ref-type="bibr" rid="ref15">15</xref>). Li (<xref ref-type="bibr" rid="ref16">16</xref>) treated 64 patients with skin adverse reactions using TCM. The results showed that the combined treatment group exhibited superior outcomes in both reduction in rash grading and clinical symptom improvement compared to the control group. Zeng (<xref ref-type="bibr" rid="ref17">17</xref>) reported favorable clinical efficacy in the treatment of rashes caused by lung cancer-targeted therapies using TCM, with treatment principles focused on clearing heat, drying dampness, detoxifying, and relieving itching.</p>
<p>Both traditional Chinese medicine nursing and Western nursing each possess distinct advantages. Western nursing, guided by modern medical diagnosis and treatment, exhibits certain strengths in controlling inflammation and mitigating toxic reactions. Traditional Chinese medicine nursing, grounded in fundamental TCM theories and incorporating holistic concepts, uses unique dialectical principles and nursing techniques to provide comprehensive care interventions for patients (<xref ref-type="bibr" rid="ref18">18</xref>). Integrating the strengths of both approaches enables more holistic care for patients experiencing skin-related adverse reactions while simultaneously reducing mortality rates (<xref ref-type="bibr" rid="ref19">19</xref>). Previous studies have indicated that Xu (<xref ref-type="bibr" rid="ref19">19</xref>) achieved favorable skin wound healing in patients with skin infections through integrated Chinese and Western nursing interventions. Wei (<xref ref-type="bibr" rid="ref20">20</xref>) used distinctive TCM nursing care for patients with toxic epidermal necrolysis, ultimately facilitating the recovery of their difficult-to-heal wounds. The state encourages mutual learning between traditional Chinese medicine and Western medicine to leverage their respective strengths and promote the integration of both medical systems. The report of the 19th National Congress of the Communist Party of China also emphasized upholding equal emphasis on traditional Chinese and Western medicine (<xref ref-type="bibr" rid="ref18">18</xref>). Consequently, integrated Chinese&#x2013;Western nursing&#x2014;a distinctive multidisciplinary team-based approach&#x2014;has gradually gained traction in clinical practice. Demonstrating significant therapeutic efficacy, it has earned recognition and endorsement from both the state and healthcare professionals, making it a key area warranting attention.</p>
<p>In 2025, a patient with severe drug-induced rash and epidermal necrosis covering more than 60% of the body surface area was admitted to our hospital&#x2019;s oncology department. The treatment and nursing care presented significant challenges. Following a multidisciplinary consultation, the patient was discharged after 6&#x202F;weeks with all skin lesions fully healed, leaving only residual hyperpigmentation. The experience of integrated Chinese and Western nursing care is reported below.</p>
</sec>
<sec id="sec2">
<label>2</label>
<title>Clinical information</title>
<sec id="sec3">
<label>2.1</label>
<title>Brief medical history</title>
<p>We present the case of a 63-year-old man who was admitted to the hospital with &#x201C;small-cell lung cancer diagnosed for 2+ months and generalized rash for 1 month&#x201D; and was diagnosed with &#x201C;small-cell lung cancer cT4N2Mx extensive stage&#x201D; after undergoing lung puncture and chest and abdominal enhancement computed tomography (CT). In the 1st and 2nd months after diagnosis, the patient received two cycles of chemotherapy and immunotherapy. The specific regimen consisted of etoposide 100&#x202F;mg IV on days 1&#x2013;3, carboplatin 300&#x202F;mg IV on day 1, and serplulimab 200&#x202F;mg IV on day 1, administered once every 3&#x202F;weeks. After two cycles of treatment, head, chest, and abdominal CT scans were reviewed, and the efficacy of the treatment was evaluated as &#x201C;partial remission.&#x201D; Notably, 3&#x202F;months after diagnosis, following the completion of the third cycle of chemotherapy + immunotherapy, the patient developed generalized erythema with itching, burning skin, and multiple blisters all over the body, which dried up and caused pain at the rupture site. The patient sought treatment in the Department of Oncology of our hospital in the fourth month after diagnosis. The patient had not used any other medication during the course of the disease and denied a history of drug or food allergies. A previous history of more than 40&#x202F;years of smoking was noted, with an average consumption of 20 cigarettes per day and no smoking cessation. No other adverse effects were observed.</p>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Treatment and regression</title>
<p>During the first week of admission, diffuse erythema was observed over the entire body, with superficial vesicles on the back, accompanied by tenderness and exudation. A large amount of desquamation was observed on the limbs, and Nikolsky&#x2019;s sign was positive on the hips. The lips and mucous membranes were swollen, while the mucous membranes showed no abnormality, and the skin involvement area was more than 80%. Combined with traditional Chinese medicine (TCM) diagnosis and treatment and the four diagnoses, the condition was identified as &#x201C;Dampness and Poison in the Skin&#x201D; (&#x201C;Dampness&#x201D; refers to an increased vascular permeability leading to the leakage of tissue fluid, lymphocytes, proteins, and other substances into the interstitial spaces or onto the skin surface, manifesting as blisters, swelling, erosion, and exudation; &#x201C;Unk&#x201D; refers to infection and inflammation presenting as redness, swelling, heat, and pain; and &#x201C;In the skin&#x201D; refers to a concentrated outbreak at the skin level) (<xref ref-type="bibr" rid="ref21">21</xref>). The TCM treatment principle was &#x201C;clearing heat and eliminating dampness and toxins,&#x201D; and the prescription was &#x201C;castor seed and dampness seepage soup plus subtraction,&#x201D; taken warm in the morning, noon, and night. The patient was also administered oral antihistamines, including loratadine and ebastine tablets (<xref ref-type="bibr" rid="ref22">22</xref>) (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Erythema and superficial erosion of the back (first week of admission).</p>
</caption>
<graphic xlink:href="fmed-13-1759311-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Close-up clinical photograph of a patient&#x2019;s back showing areas of redness labeled as erythema and multiple darkened superficial skin erosions, with red arrows highlighting the affected regions for clinical reference.</alt-text>
</graphic>
</fig>
<p>In the second week of admission, the patient had large diffuse dark red patches on the face, trunk, and limbs, on which vesicles could be observed. Vesicles of varying sizes, blood crusts, and exudation were observed on the lips, mouth, and external genitalia, along with a large area of peripheral skin peeling off together with oozing blood. Based on traditional Chinese medicine (TCM) diagnosis, this was identified as &#x201C;Fire Toxin Invading the Interior Syndrome&#x201D; (&#x201C;Fire Toxin&#x201D; refers to a bacterial infection accompanied by the release of large amounts of bacterial toxins into the bloodstream and &#x201C;Invading the Interior&#x201D; refers to the progression of a localized infection into a systemic infection) (<xref ref-type="bibr" rid="ref21">21</xref>). The prescribed TCM treatment principle was &#x201C;clearing the camp and cooling the blood, opening up and detoxifying the body,&#x201D; and the prescription was &#x201C;detoxification and cooling the blood soup plus subtraction&#x201D; (<xref ref-type="bibr" rid="ref22">22</xref>). Simultaneously, the patient received an intravenous injection of cefozoxime sodium to prevent infection and an intravenous injection of human immunoglobulin to improve the immune system (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Large peripheral skin peeling with blood oozing (second week of admission).</p>
</caption>
<graphic xlink:href="fmed-13-1759311-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Severe skin injury on an adult&#x2019;s torso and arm showing extensive redness, multiple areas of blood oozing, large patches of skin peeling, and prominent blisters, each identified with labeled arrows.</alt-text>
</graphic>
</fig>
<p>In the third week of admission, the patient&#x2019;s erythema had obviously darkened. Blisters had dried up, scabbed, and flaked, revealing new skin, and there was no obvious exudation. Based on TCM diagnosis and the four other diagnoses, the patient was identified as having &#x201C;Spleen Deficiency and Yin Injury Syndrome&#x201D; (&#x201C;Spleen Deficiency&#x201D; refers to a diminished capacity to convert food into energy and nutrients, and &#x201C;Yin Injury&#x201D; refers to a fluid and electrolyte imbalance accompanied by a reduction in tissue fluids and secretions) (<xref ref-type="bibr" rid="ref21">21</xref>). The treatment principle was to &#x201C;replenish qi to strengthen the spleen and benefit the stomach to nourish the yin,&#x201D; and the prescribed formula was &#x201C;Ginseng Ling Bai Zhu San plus reduction&#x201D; (<xref ref-type="bibr" rid="ref22">22</xref>) (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Erythema darkened significantly, blisters dried up, crusted, flaked, and new skin appeared (third week of admission).</p>
</caption>
<graphic xlink:href="fmed-13-1759311-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Medical photograph showing a person's torso with extensive bandaging, visible wounds, and dark scabbed areas labeled as blisters and scabs, and lighter pink regions labeled as newborn skin, indicating severe skin damage and healing stages.</alt-text>
</graphic>
</fig>
<p>2.2.4 In the fourth week of admission, the majority of scabs on the head, face, trunk, and limbs had fallen off. The original vesicles on the external genitalia had completely healed, with no new lesions observed. Oral TCM treatment, intravenous albumin, and other supportive treatments were continued. After more than 1&#x202F;month of hospitalization, all skin lesions had healed, the body temperature had stabilized, and the patient reported no discomfort.</p>
</sec>
</sec>
<sec sec-type="discussion" id="sec5">
<label>3</label>
<title>Discussion</title>
<p>Immunosuppressants are monoclonal antibodies that activate the immune system to enhance antitumor immunity. However, immunotherapy-related adverse reactions typically affect multiple organs and systems (<xref ref-type="bibr" rid="ref23">23</xref>). During immunotherapy, T cells within the body become fully activated. Satisfactory therapeutic effects can be achieved only when these activated T cells extensively infiltrate the tumor. Research has indicated that PD-1 inhibitors may lead to excessive T-cell activation, inducing the release of immune-related pro-inflammatory factors that contribute to the onset and progression of skin adverse reactions. This activation may be key in triggering severe TEN reactions, although the specific molecular and cellular mechanisms require further investigation (<xref ref-type="bibr" rid="ref11">11</xref>). On the other hand, PD-1 inhibitors can increase sensitivity to radiation and chemotherapy. When PD-1 inhibitors are combined with radiotherapy or chemotherapy, enhanced monitoring of adverse reactions is required (<xref ref-type="bibr" rid="ref24">24</xref>). Immunotherapy disrupts the previously balanced immune system, leading to a series of immune-related adverse reactions. These reactions differ fundamentally from those associated with traditional chemotherapy and targeted drugs, and some severe immune-related adverse reactions may be fatal (<xref ref-type="bibr" rid="ref9">9</xref>). Therefore, a thorough understanding of the mechanisms underlying immune-related adverse reactions, a mastery of the characteristics of their occurrence, and close monitoring of patient responses during treatment are crucial for the nursing management of adverse reactions following immunotherapy and the development of effective nursing interventions.</p>
<sec id="sec6">
<label>3.1</label>
<title>Skin lesion management</title>
<sec id="sec7">
<label>3.1.1</label>
<title>Nursing care of skin lesions</title>
<p>The dressing change plan for skin lesions is key to skin lesion management. According to the assessment of skin lesions, skin progression can be divided into an erythematous blistering stage, a skin peeling stage, and an epithelial crawling stage; therefore, the development of a scientific and detailed drug change program and the implementation of targeted nursing measures are important initiatives. Owing to the rarity of this disease, few prospective studies have analyzed the specific adjuvant efficacy of drugs for TEN, resulting in the absence of specific treatment standards. Currently, a widely accepted approach emphasizes supportive therapy and wound care (<xref ref-type="bibr" rid="ref25">25</xref>). However, the efficacy of surgical debridement is controversial. Evidence suggests that surgical debridement combined with drug adjuvant therapy can significantly alleviate symptoms and improve the prognosis. Glucocorticoids were the earliest effective drugs for treating TEN. The early administration of adequate glucocorticoid doses can control skin lesions, reduce inflammatory exudation, shorten disease duration, and decrease mortality (<xref ref-type="bibr" rid="ref26">26</xref>). However, long-term steroid use increases the risk of skin and mucosal infections and leads to disease recurrence. Therefore, this study used surgical debridement combined with adjunctive medicine (TCM).</p>
<p>Traditional Chinese medicine&#x2019;s holistic theory views the human body as an integrated system where physical form and mental state (emotions and consciousness) mutually influence each other and are inseparable. Illness often manifests as a dual imbalance of &#x201C;form&#x201D; (physical symptoms) and &#x201C;spirit&#x201D; (emotional) (<xref ref-type="bibr" rid="ref27">27</xref>). Single therapies often struggle to address both aspects simultaneously. Therefore, oral therapies primarily regulate the internal organs&#x2019; qi and blood. External therapies directly target meridians, skin regions, and acupoints to unblock local qi and blood circulation on the body surface. Music therapy directly regulates the mind and spirit, calming emotions (<xref ref-type="bibr" rid="ref20">20</xref>). Combining multiple TCM therapies enables simultaneous intervention at different levels (physiological and psychological) and through diverse pathways (oral absorption, skin penetration, and psychological induction). This approach shortens treatment duration, enhances efficacy, and reduces the side effects and limitations of single therapies.</p>
<p>More than 80% of the patient&#x2019;s skin was involved, making infection prevention a key priority. Therefore, the patient was transferred to a single room, and the room was disinfected with ultraviolet light twice a day for 30&#x202F;min each time. The temperature and humidity of the room were suitable, ventilation was provided for 30&#x202F;min a day, and the floor and surfaces of objects were wiped twice a day with a 1,000&#x202F;mg/L solution of chlorine-containing disinfectant. Sterile bedclothes and sheets were changed every day to create a good environment in the hospital room. In the first week of admission, the patient had diffuse erythema all over the body, and superficial erosion was observed based on erythema on the back, accompanied by tenderness and exudation. <italic>Angelica sinensis</italic> and six yellow soups were chosen for external application to the lesions to clear away heat and dampness, detoxify the toxin, and alleviate pain (<xref ref-type="bibr" rid="ref22">22</xref>). Comfrey oil was applied externally to the inguinal and axillary areas to clear away heat and detoxify the toxin (<xref ref-type="bibr" rid="ref22">22</xref>). One week later, the patient&#x2019;s erosive surface showed no enlargement, tenderness had decreased, and exudate had diminished. In the second week of admission, the patient&#x2019;s skin progressed to the erythema blister stage. For blisters with a diameter of 2&#x202F;cm and above, iodine povidone was used to disinfect the blisters and surrounding skin. A 1-mL sterile syringe needle was connected to a 5-mL sterile syringe, and the blisters were carefully punctured along the root of the blisters in a direction parallel to the skin. The blisters were then gently squeezed with a sterile swab to preserve the epidermis as much as possible and to minimize local injury. Small blisters with a diameter of &#x003C;2&#x202F;cm should be protected to promote their self-absorption, and large blisters with loose epidermis that have not been detached should not be removed from the blister skin but can be retained in the original place to act as biological dressings (<xref ref-type="bibr" rid="ref28">28</xref>). If the epidermis is detached, necrotic, and adheres to the wound in piles, the easily removable portions can be removed directly, whereas the areas that are difficult to remove should not be forcibly removed and can be cut with sterilized scissors (<xref ref-type="bibr" rid="ref29">29</xref>). Following the above skin care regimen maximizes preservation of the patient&#x2019;s skin barrier function. During this period, the patient developed no secondary skin infections. Skin erythema noticeably faded, while vesicles and bullae dried, crusted over, and desquamated. New skin emerged with no significant exudation observed. During the fourth week of admission, the patient entered the epithelial crawling period. During this stage, recombinant human epidermal growth factor was applied to the skin lesion surfaces to accelerate the growth of granulation tissue and epithelial cell proliferation (<xref ref-type="bibr" rid="ref30">30</xref>). In addition, the newly formed skin tissue was carefully protected to avoid dragging, pulling, tugging, and other actions. At this stage, the majority of scabs on the patient&#x2019;s head, face, trunk, and limbs had fallen off. The original erosive lesions on the external genitalia have completely healed, with no new skin lesions developing.</p>
</sec>
</sec>
<sec id="sec8">
<label>3.2</label>
<title>Pain management</title>
<sec id="sec9">
<label>3.2.1</label>
<title>TCM for pain relief</title>
<p>The beneficial stimulation created by herbal compresses on the painful areas and surrounding acupoints helps regulate the flow of qi and blood within the meridians, alleviating muscle spasms and tissue adhesions to improve pain at a functional level (<xref ref-type="bibr" rid="ref31">31</xref>). This therapy combines the pharmacological effects of herbs with the physical warmth of heat, synergistically promoting local blood circulation and accelerating the elimination of metabolic waste, thereby achieving a multipathway intervention for pain symptoms (<xref ref-type="bibr" rid="ref32">32</xref>). Clinical practice has shown that herbal compresses provide an effective adjunctive treatment for various acute and chronic pain conditions, including soft tissue injuries, arthritis, and postoperative pain. This therapy offers a relatively safe administration and flexible formulation option, making it a valuable component of multimodal pain management strategies (<xref ref-type="bibr" rid="ref31">31</xref>). Skin itching and pain are often associated with &#x201C;blood deficiency with wind-dryness&#x201D; and &#x201C;damp-heat accumulation in the skin.&#x201D; The <italic>Angelica six yellow soup</italic>, composed of herbs that nourish yin and blood while clearing heat and drying dampness, precisely addresses these pathomechanisms (<xref ref-type="bibr" rid="ref33">33</xref>). <italic>Angelica sinensis</italic> replenishes and activates blood circulation, thereby improving skin microcirculation and nutritional status. <italic>Radix Rehmanniae Praeparata</italic> nourishes yin and moistens dryness, alleviating itching caused by dryness. <italic>Scutellaria baicalensis</italic>, <italic>Coptis chinensis</italic>, and <italic>Cyperus rotundus</italic> clear heat and dry dampness, thereby reducing inflammatory responses; <italic>Astragalus membranaceus</italic> fortifies the exterior and strengthens the skin barrier (<xref ref-type="bibr" rid="ref34">34</xref>). This formula embodies the TCM therapeutic principle of &#x201C;nourishing blood to moisturize the skin while clearing heat and drying dampness.&#x201D; <italic>Angelica six yellow soup</italic> exhibits significant clinical efficacy in treating patients with pruritus and skin pain (<xref ref-type="bibr" rid="ref35">35</xref>). Peng achieved satisfactory therapeutic outcomes with high safety profiles when applying this formula to dermatological conditions such as pruritus and pain (<xref ref-type="bibr" rid="ref34">34</xref>). Liu (<xref ref-type="bibr" rid="ref33">33</xref>) conducted clinical observations on pruritus patients treated with <italic>Angelica six yellow soup</italic>, reporting marked therapeutic effects.</p>
<p>In the first and second weeks of admission, patients with superficial skin erosion with tenderness were treated with Chinese medicine wet compresses using <italic>Angelica six yellow soup.</italic> The medicinal ingredients included <italic>Angelica sinensis</italic>, <italic>Scutellaria baicalensis</italic>, <italic>Coptis chinensis</italic>, <italic>Cyperus rotundus</italic>, <italic>Radix Rehmanniae Praeparata</italic>, and <italic>Astragalus membranaceu</italic>s. This therapy was primarily used to reduce swelling and relieve pain, inhibit and prevent infections, astringe and stop itching, and promote the healing of trauma (<xref ref-type="bibr" rid="ref22">22</xref>). The procedure (<xref ref-type="bibr" rid="ref36">36</xref>) involved applying wet compresses with four layers of gauze. The gauze should be applied smoothly over the affected skin area, with edges extending approximately 3-4 centimeters beyond the lesion. Apply drops to the dressing every 10 minutes to maintain moisture, twice daily. One course of treatment lasted 5&#x202F;days and was used for managing skin scabs and flaking. Chinese medicine wet compression therapy can make liquid pass through the skin, have a pore effect on the whole body, clear dampness and heat, dredge qi and blood, and stop itching and pain. Following treatment, the patient experienced significant relief from skin pain and itching, with scabbing and desquamation occurring as new skin formed.</p>
</sec>
<sec id="sec10">
<label>3.2.2</label>
<title>Western medicine treatment for pain relief</title>
<p>In the third week of hospitalization, during the patient&#x2019;s skin peeling period, pain was prominent. The Numerical Rating Scale (NRS) was 9 points, and the area of epidermal loosening and peeling exceeded 56%. For effective pain relief, the patient was instructed to take oral tramadol extended-release tablets twice daily, and subcutaneous morphine was administered as needed for severe pain. Following treatment, the patient&#x2019;s pain was relieved, with a NRS score of 3.</p>
</sec>
</sec>
<sec id="sec11">
<label>3.3</label>
<title>Management of five-element music therapy in emotions and spirits</title>
<p>Itching and pain often stem from insufficient liver blood, excessive liver fire, and impaired qi and blood circulation. The nature of skin itching and pain frequently plunges patients into excessive worry, which, in turn, damages the spleen. Once the spleen is impaired, it inevitably depletes qi and blood, adversely affecting the patient&#x2019;s overall health (<xref ref-type="bibr" rid="ref37">37</xref>). Selecting tranquil music in the &#x201C;Yu&#x201D; nourishes kidney yin and calms excessive liver yang, thereby alleviating itching. Fluid, melodious music in the &#x201C;Jue&#x201D; or &#x201C;Zhi&#x201D; modes regulates the movement of qi, promotes qi and blood circulation, and relieves pain caused by stagnation. Steady, harmonious music in the &#x201C;Gong&#x201D; or &#x201C;Shang&#x201D; strengthens spleen and stomach function, indirectly achieving qi-nourishing, blood-tonifying, and pain-relieving effects (<xref ref-type="bibr" rid="ref37">37</xref>). In recent years, the efficacy of five-element music therapy has also been validated in treating skin diseases. Weng (<xref ref-type="bibr" rid="ref20">20</xref>) applied this therapy to care for patients with TEN. Their emotions gradually stabilized, qi flow improved, and symptoms such as heat toxin and blood stasis were alleviated, thereby promoting recovery.</p>
<p>Pentatonic music therapy is a form of music therapy based on TCM fundamental theories for organ differentiation. It centers on the concept of nurturing both the body and spirit, adhering to the therapeutic principles of tailoring music to the individual, season, and specific condition. This approach uses music in five distinct pitches&#x2014;&#x201C;Gong, Shang, Jue, Zhi, and Yu&#x201D;&#x2014;to intervene in disease management (<xref ref-type="bibr" rid="ref38">38</xref>). TCM emotional care is a psychosocial nursing model with the distinctive characteristics of Chinese medicine. It uses psychological counseling grounded in the TCM pattern differentiation theory, exhibiting positive effects in alleviating the patients&#x2019; negative emotions (<xref ref-type="bibr" rid="ref39">39</xref>). Research (<xref ref-type="bibr" rid="ref40">40</xref>) has indicated that TCM five-tone therapy helps regulate the human qi mechanisms and emotional states, improving anxiety and depression in patients with cancer. Patients with generalized skin eruptions, limited disease awareness, and severe anxiety were administered five-element music therapy to balance yin and yang, regulate qi and blood, and balance the dynamics of qi and qi. The doctor-in-charge of treatment prescribed music in the different keys of &#x201C;Gong, Shang, Yu, Jiao, and Zheng&#x201D; according to the patient&#x2019;s symptoms at different times. Listening to the five elements of music while regulating the patient&#x2019;s qi and blood can have a calming effect on the mind, divert attention, and relieve the discomfort caused by skin pain. Operation method: Keep the ward environment quiet, limit visits from family and friends, and ensure a chaperone is present. Assist the patient in taking a comfortable position and have them gently close their eyes. Avoid performing nursing operations during the session. Keep the volume at 30&#x2013;40 decibels and guide the patient to follow the rhythm of the music using breathing relaxation and imagery training. If the patient experiences any discomfort during the treatment, the medical staff should be informed promptly. Following treatment, the patient&#x2019;s anxiety levels decreased, and the discomfort caused by skin tenderness was alleviated.</p>
</sec>
<sec id="sec12">
<label>3.4</label>
<title>Fluid loss management and nutritional support</title>
<p>Extensive skin lesions cause significant fluid loss, making the maintenance of fluid and electrolyte balance particularly critical. While providing active fluid support, it is essential to prevent secondary harm from fluid overload (<xref ref-type="bibr" rid="ref41">41</xref>). Given the patient&#x2019;s hypoalbuminemic state, human albumin infusion was administered to increase the colloid osmotic pressure, supplemented by appropriate plasma transfusion to ensure effective circulating blood volume and maintain fluid balance. This patient typically requires 10&#x2013;20% more fluid replacement than patients with equivalent burn areas, with the urine output controlled at 50&#x2013;80&#x202F;mL/h (<xref ref-type="bibr" rid="ref42">42</xref>).</p>
<p>Studies have indicated that early enteral and parenteral nutrition in patients with TEN promotes and maintains the integrity of intestinal mucosal structure and barrier function. This approach effectively corrects malnutrition, enhances immune function, reduces the incidence of related complications, lowers the mortality rates, and improves prognosis (<xref ref-type="bibr" rid="ref43">43</xref>). The nutritional assessment tool NRS2002, introduced by the European Society for Enteral Parenteral Nutrition in 2002, is recommended as the preferred tool for nutritional risk screening of hospitalized patients in Europe. The patient had orofacial erosion, difficulty in eating, poor appetite, extreme emaciation, and a nutritional status score of 4, requiring nutritional support intervention. The medical staff established central venous access via peripheral placement and infused amino acids and fat milk to improve nutrition, to promote recovery and healing of the body, and to maintain good strength and functional status. During the second week of nutritional support, the patient exhibited a significant reduction in bleeding and exudate at the skin lesion sites, with an effective 20% decrease in the affected area. Additionally, the patient gained 1.5&#x202F;kg in body weight compared to previous measurements.</p>
</sec>
</sec>
<sec id="sec13">
<label>4</label>
<title>Research limitations</title>
<p>(1) This study reports only one patient&#x2019;s care, resulting in limited robustness and generalizability of findings. Future prospective or retrospective studies with larger sample sizes are needed to validate and support these results. (2) This study lacks organized biochemical data for the patient, and no long-term follow-up data were collected after the patient&#x2019;s discharge following treatment completion. Future research should consider longitudinal tracking and refine multi-faceted observational indicators to provide more comprehensive scientific evidence.</p>
</sec>
<sec id="sec14">
<label>5</label>
<title>Summary</title>
<p>With the widespread clinical application of tumor immunotherapy, immune-related adverse events (irAEs) with unclear mechanisms are becoming a significant challenge affecting the quality of life and long-term survival of patients. Against this backdrop, the integrated diagnostic and therapeutic pathways of Chinese and Western medicine exhibit unique advantages. Even when confronted with specific adverse reactions rarely reported in clinical studies, this model enables timely pathogenesis analysis and syndrome differentiation through the systematic collection of TCM diagnostic information, thereby rapidly formulating personalized treatment plans. Practice has shown that such interventions promote clinical symptom relief, control disease progression, and improve prognosis. TCM encompasses a wide range of therapeutic approaches, including not only oral decoctions but also diverse formulations, such as topical preparations and herbal injections. With accurate pattern identification, the judicious selection of non-oral routes of administration often results in rapid therapeutic effects. Therefore, clinical practice should not rigidly adhere to traditional medication patterns but should focus on exploring synergistic mechanisms among different treatment modalities. This field requires rigorously designed clinical trials to provide high-level medical evidence for the integrated application of multiple TCM therapies, thereby advancing scientific development and clinical implementation. This study presents experience in integrated Chinese and Western nursing care for toxic epidermal necrolysis, aiming to provide reference and insights for future nursing professionals managing related conditions. It aims to refine nursing protocols and contribute traditional Chinese nursing perspectives toward establishing high-quality care pathways for skin-related adverse reactions in cancer patients.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec15">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material; further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="sec16">
<title>Ethics statement</title>
<p>Ethical approval was not required for the study involving human samples in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec sec-type="author-contributions" id="sec17">
<title>Author contributions</title>
<p>DW: Writing &#x2013; original draft.</p>
</sec>
<sec sec-type="COI-statement" id="sec18">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec19">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec20">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname> <given-names>F</given-names></name> <name><surname>Laversanne</surname> <given-names>M</given-names></name> <name><surname>Sung</surname> <given-names>H</given-names></name> <name><surname>Ferlay</surname> <given-names>J</given-names></name> <name><surname>Siegel</surname> <given-names>RL</given-names></name> <name><surname>Soerjomataram</surname> <given-names>I</given-names></name> <etal/></person-group>. <article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. (<year>2020</year>) <volume>71</volume>:<fpage>209</fpage>&#x2013;<lpage>49</lpage>. doi: <pub-id pub-id-type="doi">10.3322/caac.21834</pub-id></mixed-citation></ref>
<ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudin</surname> <given-names>CM</given-names></name> <name><surname>Brambilla</surname> <given-names>E</given-names></name> <name><surname>Faivre-Finn</surname> <given-names>C</given-names></name> <name><surname>Sage</surname> <given-names>J</given-names></name></person-group>. <article-title>Small-cell lung cancer</article-title>. <source>Nat Rev Dis Primers</source>. (<year>2021</year>) <volume>7</volume>:<fpage>3</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41572-020-00235-0</pub-id>, <pub-id pub-id-type="pmid">33446664</pub-id></mixed-citation></ref>
<ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>SD</given-names></name> <name><surname>Xiao</surname> <given-names>YS</given-names></name> <name><surname>Wu</surname> <given-names>ZY</given-names></name></person-group>. <article-title>Efficacy of serplulimab combined with albumin-bound paclitaxel and cisplatin in patients with advanced lung squamous cell carcinoma</article-title>. <source>Cancer Prog</source>. (<year>2024</year>) <volume>22</volume>:<fpage>2282</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.11877/j.issn.1672-1535.2024.22.20.20</pub-id></mixed-citation></ref>
<ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>X</given-names></name> <name><surname>Deng</surname> <given-names>H</given-names></name> <name><surname>Li</surname> <given-names>S</given-names></name> <name><surname>Xie</surname> <given-names>X</given-names></name> <name><surname>Chen</surname> <given-names>C</given-names></name> <name><surname>Cai</surname> <given-names>L</given-names></name> <etal/></person-group>. <article-title>Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study</article-title>. <source>J Cancer Res Clin Oncol</source>. (<year>2023</year>) <volume>149</volume>:<fpage>757</fpage>&#x2013;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00432-021-03903-0</pub-id></mixed-citation></ref>
<ref id="ref5"><label>5.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ge</surname> <given-names>YX</given-names></name></person-group>. <source>Clinical study comparing the efficacy and safety of Serplulimab vs neoadjuvant chemotherapy in neoadjuvant immunotherapy for PD-L1-positive stage IIA-IIIb non-small cell lung Cancer</source>. <publisher-loc>Hu Bei</publisher-loc>: <publisher-name>Yangtze University</publisher-name> (<year>2025</year>).</mixed-citation></ref>
<ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Cleach</surname> <given-names>L</given-names></name> <name><surname>Delaire</surname> <given-names>S</given-names></name> <name><surname>Boumsell</surname> <given-names>L</given-names></name> <name><surname>Bagot</surname> <given-names>M</given-names></name> <name><surname>Bourgault-Villada</surname> <given-names>I</given-names></name> <name><surname>Bensussan</surname> <given-names>A</given-names></name> <etal/></person-group>. <article-title>Blister fluid T lymphocytes during toxic epiderm al necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitor y receptors</article-title>. <source>Clin Exp Immunol</source>. (<year>2000</year>) <volume>119</volume>:<fpage>225</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01119.x</pub-id>, <pub-id pub-id-type="pmid">10606987</pub-id></mixed-citation></ref>
<ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>Y</given-names></name> <name><surname>Han</surname> <given-names>L</given-names></name> <name><surname>Wu</surname> <given-names>L</given-names></name> <name><surname>Chen</surname> <given-names>J</given-names></name> <name><surname>Sun</surname> <given-names>H</given-names></name> <name><surname>Wen</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title>Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the astrum-005 randomized clinical trial</article-title>. <source>JAMA</source>. (<year>2022</year>) <volume>328</volume>:<fpage>1223</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2022.16464</pub-id>, <pub-id pub-id-type="pmid">36166026</pub-id></mixed-citation></ref>
<ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>DY</given-names></name> <name><surname>Salem</surname> <given-names>JE</given-names></name> <name><surname>Cohen</surname> <given-names>JV</given-names></name> <name><surname>Chandra</surname> <given-names>S</given-names></name> <name><surname>Menzer</surname> <given-names>C</given-names></name> <name><surname>Ye</surname> <given-names>F</given-names></name> <etal/></person-group>. <article-title>Fatal toxic effects associated with immune checkp oint inhibitors: a systematic review and meta-analysis</article-title>. <source>JAMA Oncol</source>. (<year>2018</year>) <volume>4</volume>:<fpage>1721</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaoncol.2018.3923</pub-id></mixed-citation></ref>
<ref id="ref9"><label>9.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tu</surname> <given-names>KY</given-names></name></person-group>. <source>Clinical study on immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis</source>. <publisher-loc>Jiang Xi</publisher-loc>: <publisher-name>Nanchang University</publisher-name> (<year>2025</year>).</mixed-citation></ref>
<ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>HL</given-names></name> <name><surname>Li</surname> <given-names>Y</given-names></name></person-group>. <article-title>Nursing care for a patient with toxic epidermal necrolysis following gastric cancer radical surgery after immune checkpoint inhibitor therapy</article-title>. <source>Chin J Clin Nurs</source>. (<year>2025</year>) <volume>17</volume>:<fpage>63</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.3969/j.issn.1674-3768.2025.01.014</pub-id></mixed-citation></ref>
<ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>Q</given-names></name> <name><surname>Guo</surname> <given-names>Y</given-names></name> <name><surname>Wu</surname> <given-names>HJ</given-names></name> <name><surname>Yang</surname> <given-names>QL</given-names></name> <name><surname>Wang</surname> <given-names>GW</given-names></name> <etal/></person-group>. <article-title>Nursing management of a case of IrAEs grade 2 with bullous dermatitis/toxic epidermal necrolysis induced by Tislelizumab</article-title>. <source>Gansu Med</source>. (<year>2025</year>) <volume>44</volume>:<fpage>282</fpage>&#x2013;<lpage>284+288</lpage>. doi: <pub-id pub-id-type="doi">10.15975/j.cnki.1004-2725.2025.03.023</pub-id></mixed-citation></ref>
<ref id="ref12"><label>12.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>YH</given-names></name></person-group>. <source>Clinical characteristics and retrospective analysis of bullous pemphigoid-like drug eruption induced by anti-PD-1 inhibitors</source>. <publisher-loc>Jiang Su</publisher-loc>: <publisher-name>Soochow University</publisher-name> (<year>2021</year>).</mixed-citation></ref>
<ref id="ref13"><label>13.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>K</given-names></name></person-group>. <source>Network Meta-analysis of five systemic immunotherapies for Stevens-Johnson syndrome and toxic epidermal necrolysis</source>, <publisher-loc>Shan Dong</publisher-loc>: <publisher-name>Qingdao University</publisher-name> (<year>2020</year>).</mixed-citation></ref>
<ref id="ref14"><label>14.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name></person-group>. <source>Clinical observation on the efficacy of Siwu Xiaofeng decoction in treating immune checkpoint inhibitor-related skin toxicity</source>, <publisher-loc>Ji Lin</publisher-loc>: <publisher-name>Changchun University of Chinese Medicine</publisher-name> (<year>2024</year>).</mixed-citation></ref>
<ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>Q</given-names></name> <name><surname>Ji</surname> <given-names>Q</given-names></name> <name><surname>Li</surname> <given-names>Q</given-names></name></person-group>. <article-title>Clinical and mechanistic studies on traditional Chinese medicine modulating tumor immunity</article-title>. <source>J Chin Med Tradit Chin Med</source>. (<year>2018</year>) <volume>33</volume>:<fpage>4542</fpage>&#x2013;<lpage>5</lpage>. Available at: <ext-link xlink:href="https://d.wanfangdata.com.cn/periodical/zgyyxb201810075" ext-link-type="uri">https://d.wanfangdata.com.cn/periodical/zgyyxb201810075</ext-link></mixed-citation></ref>
<ref id="ref16"><label>16.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>ZX</given-names></name></person-group>. <source>Clinical observation of lung-nourishing and rash-eliminating formula in treating targeted drug-related rash in lung Cancer patients</source>. <publisher-loc>Tianjin</publisher-loc>: <publisher-name>Tianjin University of Traditional Chinese Medicine</publisher-name> (<year>2023</year>).</mixed-citation></ref>
<ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>YH</given-names></name> <name><surname>Zeng</surname> <given-names>S</given-names></name></person-group>. <article-title>Zeng sheng's experience in treating epidermal growth factor receptor tyrosine kinase inhibitor-related rash using the theory of blood heat and damp-toxin</article-title>. <source>Chin Folk Ther</source>. (<year>2022</year>) <volume>30</volume>:<fpage>37</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.19621/j.cnki.11-3555/r.2022.0914</pub-id></mixed-citation></ref>
<ref id="ref18"><label>18.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>JM</given-names></name></person-group>. <source>Development of an integrated Chinese and Western medicine nursing protocol for grade 0 diabetic foot</source>, <publisher-loc>Guang Xi</publisher-loc>: <publisher-name>Guangxi University of Chinese Medicine</publisher-name> (<year>2023</year>).</mixed-citation></ref>
<ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>N</given-names></name></person-group>. <article-title>Observation on the efficacy of integrated Chinese and western nursing for hand-foot syndrome in chemotherapy patients with malignant tumors</article-title>. <source>Contemp Nurse (First Half Ed)</source>. (<year>2019</year>) <volume>26</volume>:<fpage>71</fpage>&#x2013;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.3969/j.issn.1006-6411.2019.11.031</pub-id></mixed-citation></ref>
<ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname> <given-names>TT</given-names></name></person-group>. <article-title>A case of toxic epidermal necrolysis treated with traditional Chinese medicine-based nursing</article-title>. <source>Chin Rural Med</source>. (<year>2025</year>) <volume>32</volume>:<fpage>55</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.19542/j.cnki.1006-5180.2501-243</pub-id></mixed-citation></ref>
<ref id="ref21"><label>21.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>C D</given-names></name></person-group> <source>Chinese Medical Diagnosis [M]</source> <publisher-loc>Beijing</publisher-loc> <publisher-name>China Traditional Chinese Medicine Press</publisher-name> (<year>2021</year>) <fpage>126</fpage>&#x2013;<lpage>151</lpage></mixed-citation></ref>
<ref id="ref22"><label>22.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name></person-group>. <source>Formulary science</source>. <publisher-loc>Beijing</publisher-loc>: <publisher-name>China Traditional Chinese Medicine Press</publisher-name> (<year>2021</year>).</mixed-citation></ref>
<ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname> <given-names>XY</given-names></name> <name><surname>He</surname> <given-names>CX</given-names></name> <name><surname>Zhang</surname> <given-names>L</given-names></name> <name><surname>Si</surname> <given-names>X</given-names></name> <name><surname>He</surname> <given-names>C</given-names></name> <name><surname>Liu</surname> <given-names>X</given-names></name> <etal/></person-group>. <article-title>Management of immune checkpoint inhibitor-related dermatologic adverse events</article-title>. <source>Thorac Cancer</source>. (<year>2020</year>) <volume>11</volume>:<fpage>488</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1759-7714.13275</pub-id>, <pub-id pub-id-type="pmid">31814310</pub-id></mixed-citation></ref>
<ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>ZY</given-names></name> <name><surname>Shen</surname> <given-names>J</given-names></name> <name><surname>Yang</surname> <given-names>YW</given-names></name> <name><surname>Xu</surname> <given-names>Z</given-names></name> <name><surname>Yang</surname> <given-names>Y</given-names></name> <name><surname>Yuan</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>Severe cutaneous adverse reactions: a single-center retrospective study of 173 patients in China</article-title>. <source>Ann Dermatol</source>. (<year>2019</year>) <volume>31</volume>:<fpage>545</fpage>&#x2013;<lpage>54</lpage>. doi: <pub-id pub-id-type="doi">10.5021/ad.2019.31.5.545</pub-id>, <pub-id pub-id-type="pmid">33911647</pub-id></mixed-citation></ref>
<ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname> <given-names>S</given-names></name> <name><surname>Sekula</surname> <given-names>P</given-names></name> <name><surname>Venhoff</surname> <given-names>M</given-names></name> <name><surname>Motschall</surname> <given-names>E</given-names></name> <name><surname>Knaus</surname> <given-names>J</given-names></name> <name><surname>Schumacher</surname> <given-names>M</given-names></name> <etal/></person-group>. <article-title>Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis</article-title>. <source>JAMA Dermatol</source>. (<year>2017</year>) <volume>153</volume>:<fpage>514</fpage>. doi: <pub-id pub-id-type="doi">10.1001/jamadermatol.2016.5668</pub-id></mixed-citation></ref>
<ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname> <given-names>QW</given-names></name> <name><surname>Ma</surname> <given-names>HC</given-names></name></person-group>. <article-title>Research progress on toxic epidermal necrolysis</article-title>. <source>J Shandong Med Coll</source>. (<year>2025</year>) <volume>47</volume>:<fpage>23</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.3969/j.issn.1674-0947.2025.04.009</pub-id></mixed-citation></ref>
<ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>JJ</given-names></name> <name><surname>Jia</surname> <given-names>YY</given-names></name> <name><surname>Shao</surname> <given-names>F</given-names></name></person-group>. <article-title>Reflections on optimizing traditional Chinese medicine nursing for critically ill cancer patients</article-title>. <source>J Tradit Chin Med Manag</source>. (<year>2025</year>) <volume>33</volume>:<fpage>127</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.16690/j.cnki.1007-9203.2025.20.037</pub-id></mixed-citation></ref>
<ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>XL</given-names></name> <name><surname>Guo</surname> <given-names>Q</given-names></name> <name><surname>Luan</surname> <given-names>H</given-names></name> <name><surname>Zhao</surname> <given-names>X</given-names></name></person-group>. <article-title>Management of skin lesions in a patient with severe toxic epidermal necrolytic loosening drug rash</article-title>. <source>Chin Nurs Res</source>. (<year>2024</year>) <volume>38</volume>:<fpage>937</fpage>&#x2013;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.12102/j.issn.1009-6493.2024.05.033</pub-id></mixed-citation></ref>
<ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>MQ</given-names></name> <name><surname>Qin</surname> <given-names>HY</given-names></name></person-group>. <article-title>Progress of skin care research on Stevens-Johnson syndrome and toxic epidermal necrolysis with laxity</article-title>. <source>Chin Nurs Res</source>. (<year>2019</year>) <volume>33</volume>:<fpage>4275</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.12102/j.issn.1009-6493.2019.24.017</pub-id></mixed-citation></ref>
<ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><collab id="coll1">Chinese Medical Association Burn Surgery Branch, Editorial Committee of Chinese Burn Journal</collab>. <article-title>Clinical guidelines for the topical use of growth factors in cutaneous trauma</article-title>. <source>Chin J Burns</source>. (<year>2017</year>) <volume>33</volume>:<fpage>721</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.3760/cma.j.issn.1009-2587.2017.12.001</pub-id></mixed-citation></ref>
<ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>L</given-names></name> <name><surname>Fang</surname> <given-names>YF</given-names></name> <name><surname>Xu</surname> <given-names>JT</given-names></name> <name><surname>Wang</surname> <given-names>G</given-names></name> <name><surname>Geng</surname> <given-names>QN</given-names></name> <name><surname>Li</surname> <given-names>QJ</given-names></name> <etal/></person-group>. <article-title>Mechanism of combined blood-letting cupping and Chinese herbal wet compress in treating herpes zoster based on Th1/Th2 dysregulation and serum P substance levels</article-title>. <source>Acupunct Res</source>. (<year>2022</year>) <volume>47</volume>:<fpage>814</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.13702/j.1000-0607.20210893</pub-id></mixed-citation></ref>
<ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname> <given-names>SZ</given-names></name> <name><surname>Chen</surname> <given-names>HY</given-names></name></person-group>. <article-title>Effects of Chinese herbal wet compresses and Chinese herbal steam baths on wound healing and pain in patients after hemorrhoid surgery</article-title>. <source>China Med Guide</source>. (<year>2024</year>) <volume>22</volume>:<fpage>145</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.15912/j.issn.1671-8194.2024.35.043</pub-id></mixed-citation></ref>
<ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>CG</given-names></name> <name><surname>Lei</surname> <given-names>ZM</given-names></name> <name><surname>Zhang</surname> <given-names>Q</given-names></name> <name><surname>Song</surname> <given-names>N</given-names></name></person-group>. <article-title>Application and case studies of Angelica six yellow soup</article-title>. <source>Prim Care Tradit Chin Med</source>. (<year>2026</year>) <volume>5</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.20065/j.cnki.btcm.20260032</pub-id></mixed-citation></ref>
<ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>WB</given-names></name> <name><surname>Cai</surname> <given-names>YH</given-names></name></person-group>. <article-title>Three clinical cases of modified Angelica six yellow soup in treating dermatological diseases</article-title>. <source>New Chin Med</source>. (<year>2022</year>) <volume>54</volume>:<fpage>70</fpage>&#x2013;<lpage>2</lpage>. doi: <pub-id pub-id-type="doi">10.13457/j.cnki.jncm.2022.12.014</pub-id></mixed-citation></ref>
<ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname> <given-names>M</given-names></name> <name><surname>Wei</surname> <given-names>Y</given-names></name> <name><surname>Jiang</surname> <given-names>LJ</given-names></name> <name><surname>Li</surname> <given-names>YG</given-names></name> <name><surname>Cui</surname> <given-names>W</given-names></name> <name><surname>Zhang</surname> <given-names>WF</given-names></name> <etal/></person-group>. <article-title>Current clinical application and experimental research progress of Angelica six yellow soup in treating different diseases with the same formula</article-title>. <source>J Changchun Univ Chin Med</source>. (<year>2022</year>) <volume>38</volume>:<fpage>467</fpage>&#x2013;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.13463/j.cnki.cczyy.2022.04.029</pub-id></mixed-citation></ref>
<ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>MG</given-names></name> <name><surname>Hu</surname> <given-names>B</given-names></name> <name><surname>Ruan</surname> <given-names>N</given-names></name> <name><surname>Chen</surname> <given-names>L</given-names></name> <name><surname>Li</surname> <given-names>J</given-names></name> <name><surname>Li</surname> <given-names>YW</given-names></name> <etal/></person-group>. <article-title>Observation on the efficacy of herbal wet compresses with different thicknesses of gauze on liver meridian heat-suppressing type snake string sores lesions</article-title>. <source>Beijing J Tradit Chin Med</source>. (<year>2020</year>) <volume>39</volume>:<fpage>622</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.16025/j.1674-1307.2020.06.026</pub-id></mixed-citation></ref>
<ref id="ref37"><label>37.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ming</surname> <given-names>J</given-names></name></person-group>. <source>Application of five-element music therapy combined with Acupoint massage in continuity Care for Patients with blood-deficiency wind-dryness pattern eczema: A prospective randomized controlled clinical trial</source>, <publisher-loc>Si Chuan</publisher-loc>: <publisher-name>Chengdu University of Traditional Chinese Medicine</publisher-name> (<year>2024</year>).</mixed-citation></ref>
<ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Y</given-names></name> <name><surname>Li</surname> <given-names>Y</given-names></name> <name><surname>Gao</surname> <given-names>YK</given-names></name> <name><surname>Wang</surname> <given-names>YR</given-names></name></person-group>. <article-title>Clinical observation on 30 cases of premenopausal and postmenopausal syndrome treated with combination of medicine and music</article-title>. <source>J Liaoning Univ Tradit Chin Med</source>. (<year>2022</year>) <volume>24</volume>:<fpage>178</fpage>&#x2013;<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.13194/j.issn.1673-842x.2022.05.035</pub-id></mixed-citation></ref>
<ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname> <given-names>YB</given-names></name> <name><surname>Zhang</surname> <given-names>X</given-names></name> <name><surname>Cui</surname> <given-names>YF</given-names></name> <name><surname>Wang</surname> <given-names>J</given-names></name> <name><surname>Wang</surname> <given-names>Q</given-names></name> <name><surname>Yang</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>Strategies for emotional nursing of patients with coronavirus disease 2019</article-title>. <source>Chin J Nurs</source>. (<year>2020</year>) <volume>55</volume>:<fpage>826</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.3761/j.issn.0254-1769.2020.S1.326</pub-id></mixed-citation></ref>
<ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>ZY</given-names></name> <name><surname>Peng</surname> <given-names>XY</given-names></name> <name><surname>He</surname> <given-names>DY</given-names></name> <name><surname>Liu</surname> <given-names>JM</given-names></name></person-group>. <article-title>Research status of five-tone therapy in treating malignant tumors in traditional Chinese medicine</article-title>. <source>Hunan J Tradit Chin Med</source>. (<year>2023</year>) <volume>39</volume>:<fpage>201</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.16808/j.cnki.issn1003-7705.2023.02.044</pub-id></mixed-citation></ref>
<ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname> <given-names>JB</given-names></name> <name><surname>Gondek</surname> <given-names>SP</given-names></name> <name><surname>Troche</surname> <given-names>M</given-names></name> <name><surname>Summitt</surname> <given-names>JB</given-names></name> <name><surname>Rae</surname> <given-names>L</given-names></name> <name><surname>Thayer</surname> <given-names>WP</given-names></name> <etal/></person-group>. <article-title>The use of porcine xenografts in patients with toxic epidermal necrolysis</article-title>. <source>Burns</source>. (<year>2016</year>) <volume>42</volume>:<fpage>1728</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.burns.2016.06.003</pub-id>, <pub-id pub-id-type="pmid">27350163</pub-id></mixed-citation></ref>
<ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname> <given-names>X</given-names></name> <name><surname>Min</surname> <given-names>DH</given-names></name> <name><surname>Guo</surname> <given-names>GH</given-names></name> <name><surname>Liao</surname> <given-names>XC</given-names></name></person-group>. <article-title>Thirteen cases of toxic epidermal necrolysis</article-title>. <source>Chin J Burns</source>. (<year>2018</year>) <volume>34</volume>:<fpage>3</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.3760/cma.j.issn.1009-2587.2018.03.012</pub-id></mixed-citation></ref>
<ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>WL</given-names></name> <name><surname>Pang</surname> <given-names>JB</given-names></name> <name><surname>Li</surname> <given-names>H</given-names></name></person-group>. <article-title>Therapeutic efficacy of enteral nutrition support in patients with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)</article-title>. <source>J Parenter Enteral Nutr</source>. (<year>2025</year>) <volume>32</volume>:<fpage>151</fpage>&#x2013;<lpage>154+16</lpage>. doi: <pub-id pub-id-type="doi">10.16151/j.1007-810x.2025.03.005</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0001">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1917426/overview">Maurizio Romagnuolo</ext-link>, Fondazione IRCCS Ca&#x2019; Granda Ospedale Maggiore Policlinico di Milano, Italy</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0002">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3161650/overview">Anna Pradiningsih</ext-link>, Universitas Muhammadiyah Mataram, Indonesia</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3324640/overview">Ya-Li Zhang</ext-link>, Beijing University of Chinese Medicine, China</p>
</fn>
</fn-group>
</back>
</article>